• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL.

作者信息

Shi Hui, Zheng Peihao, Liu Rui, Xu Teng, Yang Fan, Feng Shaomei, Guo Yuelu, Ma Lixia, Liu Haidi, Lei Yang, Li Ruiting, Deng Biping, Hou Shuling, Li Yang, Zheng Qinlong, Hu Kai, Ke Xiaoyan

机构信息

Department of Hematology and Lymphoma Research Center, Beijing Boren Hospital, Beijing, China.

Department of Lymphoma, Shanxi Baiqiuen Hospital, Taiyuan, Shanxi, China.

出版信息

Blood Adv. 2023 Mar 28;7(6):1070-1075. doi: 10.1182/bloodadvances.2021006845.

DOI:10.1182/bloodadvances.2021006845
PMID:35901280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10034568/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b49/10034568/d84e181e4cbc/BLOODA_ADV-2021-006845-gr2ac.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b49/10034568/73b0792da83c/BLOODA_ADV-2021-006845-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b49/10034568/d84e181e4cbc/BLOODA_ADV-2021-006845-gr2ac.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b49/10034568/73b0792da83c/BLOODA_ADV-2021-006845-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b49/10034568/d84e181e4cbc/BLOODA_ADV-2021-006845-gr2ac.jpg

相似文献

1
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL.复发或难治性弥漫性大B细胞淋巴瘤患者中CAR T细胞免疫疗法的基因图谱与疗效
Blood Adv. 2023 Mar 28;7(6):1070-1075. doi: 10.1182/bloodadvances.2021006845.
2
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.
3
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
4
Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.定制 CARs：利用同种异体 CAR 疗法的适应性解决复发/难治性弥漫性大 B 细胞淋巴瘤中的当前挑战。
Front Immunol. 2022 May 18;13:887866. doi: 10.3389/fimmu.2022.887866. eCollection 2022.
5
Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.高肿瘤负荷复发/难治性弥漫性大 B 细胞淋巴瘤的放射致敏嵌合抗原受体 T 细胞治疗。
J Immunother. 2020 Jan;43(1):32-37. doi: 10.1097/CJI.0000000000000284.
6
[Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma].[复发/难治性弥漫性大B细胞淋巴瘤的CAR-T细胞疗法研究进展]
Zhonghua Nei Ke Za Zhi. 2019 Nov 1;58(11):849-852. doi: 10.3760/cma.j.issn.0578-1426.2019.11.017.
7
[The study of chimeric antigen receptor T (CAR-T) cell therapy in refractory/relapsed T-cell malignancies].嵌合抗原受体T（CAR-T）细胞疗法治疗难治性/复发性T细胞恶性肿瘤的研究
Zhonghua Xue Ye Xue Za Zhi. 2022 Apr 14;43(4):349-352. doi: 10.3760/cma.j.issn.0253-2727.2022.04.015.
8
CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.嵌合抗原受体T细胞（CAR-T）与异基因造血干细胞移植治疗复发/难治性B细胞急性淋巴细胞白血病
Immunotherapy. 2017 Oct;9(13):1115-1125. doi: 10.2217/imt-2017-0072.
9
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
10
Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.阿基仑赛注射液用于治疗复发/难治性B细胞非霍奇金淋巴瘤。
Drugs Today (Barc). 2018 Mar;54(3):187-198. doi: 10.1358/dot.2018.54.3.2776625.

引用本文的文献

1
The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.在CAR-T治疗后的复发CD19-CD5+弥漫性大B细胞淋巴瘤中安全有效地应用依泊妥单抗。
Blood Cell Ther. 2025 Aug 1;8(3):244-249. doi: 10.31547/bct-2024-037. eCollection 2025 Aug 25.
2
Characteristics and predictive model for diffuse large B-cell lymphoma with early chemoimmunotherapy failure.早期化疗免疫治疗失败的弥漫性大B细胞淋巴瘤的特征及预测模型
Front Immunol. 2025 Jun 16;16:1553850. doi: 10.3389/fimmu.2025.1553850. eCollection 2025.
3
Efficacy and Safety of CART Cell Therapy in Aggressive B-Cell Lymphomas Involving the Gastrointestinal Tract.

本文引用的文献

1
CAR-T Therapy, the End of a Chapter or the Beginning of a New One?嵌合抗原受体T细胞疗法，是一个篇章的结束还是新篇章的开始？
Cancers (Basel). 2021 Feb 18;13(4):853. doi: 10.3390/cancers13040853.
2
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.复发 B 细胞淋巴瘤治疗耐药的遗传和进化模式。
Blood Adv. 2020 Jul 14;4(13):2886-2898. doi: 10.1182/bloodadvances.2020001696.
3
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.具有治疗意义的弥漫性大 B 细胞淋巴瘤遗传亚型的概率分类工具。
嵌合抗原受体T细胞（CART）疗法治疗累及胃肠道的侵袭性B细胞淋巴瘤的疗效与安全性
Cancer Rep (Hoboken). 2025 Jan;8(1):e70083. doi: 10.1002/cnr2.70083.
4
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗的大B细胞淋巴瘤患者的预后生物标志物。
Hemasphere. 2024 Aug 22;8(8):e130. doi: 10.1002/hem3.130. eCollection 2024 Aug.
5
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.CD19嵌合抗原受体T细胞（CART）治疗失败后，采用挽救性CD20-SD-CART疗法治疗侵袭性B细胞淋巴瘤。
Front Oncol. 2024 Jun 25;14:1376490. doi: 10.3389/fonc.2024.1376490. eCollection 2024.
6
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.复发或难治性弥漫性大B细胞淋巴瘤基于免疫治疗的新策略进展
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
7
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.携带 TP53 突变和 DDX3X-TP53 共突变的高危亚组 rrDLBCL 的特征和预后。
Cancer Med. 2023 May;12(9):10267-10279. doi: 10.1002/cam4.5756. Epub 2023 Mar 27.
Cancer Cell. 2020 Apr 13;37(4):551-568.e14. doi: 10.1016/j.ccell.2020.03.015.
4
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.弥漫性大 B 细胞淋巴瘤的靶向测序、分子亚型与结局：血液系统恶性肿瘤研究网络报告
Blood. 2020 May 14;135(20):1759-1771. doi: 10.1182/blood.2019003535.
5
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
6
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
7
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.弥漫性大 B 细胞淋巴瘤的分子亚型与不同的发病机制和预后相关。
Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30.
8
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传学与发病机制
N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.
9
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
10
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传和功能驱动因素
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.